flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor
cells. Vaccines made from melanoma cells may make the body build an immune response to and
kill their tumor cells.
PURPOSE: Phase II trial to study the effectiveness of flt3L with or without vaccine therapy
in treating patients with metastatic melanoma or renal cell cancer.